Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“Neoadjuvant GOLP for resectable high risk cholangiocarcinoma. Small trial 178 pts total. Around 90 in each arm.
China based single center. EFS is composite end point.
- Tell me what’s the issue with OS curve?
- Do u think that needs to be highlighted?
- Can we have better conclusion of the abstract?
Title: Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
Authors: Guo-Ming Shi, Xiao-Yong Huang, Fei Liang, Xiao Liang, Rui Dong, Qing-Hai Ye, Qiang Gao, Yuan Ji, Zheng-Ping Yu, Wen-Long Zhai, Jia-Cheng Lu, Xiao-Wu Li, Fu-Bao Liu, Kui Wang, Wei Yang, Jia-Lin Zhang, Zhi-Qiang Hu, Shuang-Jian Qiu, Xiao-Ying Wang, Xin-Rong Yang, Hui-Chuan Sun, Ying-Hong Shi, Zhen-Bin Ding, Wei-Ren Liu, Xiao-Wu Huang, Cheng Huang, Ying-Hao Shen, Jian Sun, Yi-Feng He, Yuan-Fei Peng, Yang Xu, Jian-Jun Zou, Jian Zhou, Jia Fan
Read The Full Article
Other articles about Cholangiocarcinoma on OncoDaily.
